CUBT
Curative Biotechnology Inc
NYSE MKT: CUBT · HEALTHCARE · BIOTECHNOLOGY
$1.25
+1.94% today
Updated 2026-06-05
Market cap
$1.07B
P/E ratio
—
P/S ratio
158.53x
EPS (TTM)
$-0.72
Dividend yield
—
52W range
$0 – $1
Volume
0.0M
WallStSmart proprietary scores
17
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
—
—
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-185272.00
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | — | $132320.00 |
| Net income | $-5.34M | $-5.38M | $-3.96M | $-3.56M | $-482000.00 |
| EPS | — | — | — | — | $-0.72 |
| Free cash flow | $-1.63M | $-1.61M | $-500626.00 | $-1.02M | $-185272.00 |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Curative Biotechnology Inc trades at $1.25. Our Smart Value Score of 17/100 indicates the stock is weak. TTM revenue stands at $132320.00.
Frequently asked questions
What is Curative Biotechnology Inc's stock price?
Curative Biotechnology Inc (CUBT) trades at $1.25, on a P/S of 158.5x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Curative Biotechnology Inc overvalued?
Curative Biotechnology Inc carries a Smart Value Score of 17/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is Curative Biotechnology Inc's revenue?
Curative Biotechnology Inc's trailing twelve-month revenue is $132320.00. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNYSE MKT
CurrencyUSD
Quick metrics
P/S ratio158.53x
ROE-3.98%
Beta1.42
50D MA$0.03
200D MA$0.01
Shares out1.05B
Float0.86B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—